# Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

> **NCT02122770** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MLN4924
- **DRUG:** Fluconazole
- **DRUG:** Itraconazole
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02122770
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-01
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02122770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02122770, "Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02122770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*